Olga Valverde

Dr. Olga Valverde

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2007 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
EAEster Aso
Ester Aso
Andres OzaitaAndres Ozaita
Andres Ozaita
EVElsa M. Valdizán
Elsa M. Valdizán
CLCatherine Ledent
Catherine Ledent
ÁPÁngel Pazos
Ángel Pazos
OVOlga Valverde
Olga Valverde
Stress can cause damage and atrophy of neurons in the hippocampus by deregulating the expression of neurotrophic factors that promote neuronal plasticity. The endocannabinoid system represents a physiological substrate involved in neuroprotection at both cellular and emotional levels. The lack of CB1 receptor alters neuronal plasticity and originates an anxiety‐like phenotype in mice. In the present study, CB1 knockout mice exhibited an augmented response to stress revealed by the increased despair behavior and corticosterone levels showed in the tail suspension test and decreased brain derived neurotrophic factor (BDNF) levels in the hippocampus. Interestingly, local administration of BDNF in the hippocampus reversed the increased despair behavior of CB1 knockout mice, confirming the crucial role played by BDNF on the emotional impairment of these mutants. The neurotrophic deficiency seems to be specific for BDNF as no differences were found in the levels of nerve growth factor and NT‐3, two additional neurotrophic factors. Moreover, BDNF impairment is not related to the activity of its specific tyrosine kinase receptor or the activity of the transcription factor cAMP responsive element binding. These results suggest that the lack of CB1 receptor originates an enhanced response to stress and deficiency in neuronal plasticity by decreasing BDNF levels in the hippocampus that lead to impairment in the responses to emotional disturbances.

1 February 2016 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
IGIrene Gracia-Rubio
Irene Gracia-Rubio
MMMaria Moscoso-Castro
Maria Moscoso-Castro
Oscar PozoOscar Pozo
Oscar Pozo
JMJosep Marcos
Josep Marcos
RNRoser Nadal
Roser Nadal
OVOlga Valverde
Olga Valverde

1 March 2012 in Neuroscience
Verified
Journal Article
Closed access
OVOlga Valverde
Olga Valverde
MTM. Torrens
M. Torrens

1 December 2018 in Neuropharmacology
Verified
Journal Article
Closed access
MLMiguel Ángel Luján
Miguel Ángel Luján
ACAdriana Castro-Zavala
Adriana Castro-Zavala
LALaia Alegre-Zurano
Laia Alegre-Zurano
OVOlga Valverde
Olga Valverde

6 December 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
IGInes Gallego-Landin
Ines Gallego-Landin
AGAlba García-Baos
Alba García-Baos
ACAdriana Castro-Zavala
Adriana Castro-Zavala
OVOlga Valverde
Olga Valverde
Major depressive disorder is a high-impact, debilitating disease and it is currently considered the most prevalent mental illness. It is associated with disability, as well as increased morbidity and mortality. Despite its significant repercussions in our society, its exact pathophysiology remains unclear and therefore, available antidepressant treatment options are limited and, in some cases, ineffective. In the past years, research has focused on the development of a multifactorial theory of depression. Simultaneously, evidence supporting the role of the endocannabinoid system in the neurobiology of neuropsychiatric diseases has emerged. Studies have shown that the endocannabinoid system strongly impacts neurotransmission, and the neuroendocrine and neuroimmune systems, which are known to be dysfunctional in depressive patients. Accordingly, common antidepressants were shown to have a direct impact on the expression of cannabinoid receptors throughout the brain. Therefore, the relationship between the endocannabinoid system and major depressive disorder is worth consideration. Nevertheless, most studies focus on smaller pieces of what is undoubtedly a larger mosaic of interdependent processes. Therefore, the present review summarizes the existing literature regarding the role of the endocannabinoid system in depression aiming to integrate this information into a holistic picture for a better understanding of the relationship between the two.

7 April 2009 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
EAEster Aso
Ester Aso
TRThibault Renoir
Thibault Renoir
GMGuadalupe Mengod
Guadalupe Mengod
CLCatherine Ledent
Catherine Ledent
MHMichel Hamon
Michel Hamon
OVOlga Valverde
Olga Valverde
J. Neurochem. (2009) 109, 935–944. Abstract Serotonergic and endocannabinoid systems are important substrates for the control of emotional behaviour and growing evidence show an involvement in the pathophysiology of mood disorders. In the present study, the absence of the activity of the CB1 cannabinoid receptor impaired serotonergic negative feedback in mice. Thus, in vivo microdialysis experiments revealed increased basal 5-HT extracellular levels and attenuated fluoxetine-induced increase of 5-HT extracellular levels in the prefrontal cortex of CB1 knockout compared with wild-type mice. These observations could be related to the significant reduction in the 5-HT transporter binding site density detected in frontal cortex and hippocampus of CB1 knockout mice. The lack of CB1 receptor also altered some 5-HT receptors related to the 5-HT feedback. Extracellular recordings in the dorsal raphe nucleus (DRN) revealed that the genetic and pharmacological blockade of CB1 receptor induced a 5-HT1A autoreceptor functional desensitization. In situ hybridization studies showed a reduction in the expression of the 5-HT2C receptor within several brain areas related to the control of the emotional responses, such as the DRN, the nucleus accumbens and the paraventricular nucleus of the hypothalamus, whereas an over-expression was observed in the CA3 area of the ventral hippocampus. These results reveal that the lack of CB1 receptor induces a facilitation of the activity of serotonergic neurons in the DRN by altering different components of the 5-HT feedback as well as an increase in 5-HT extracellular levels in the prefrontal cortex in mice.